-
Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China
Kevin
April 28, 2025
This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.
-
A Comparison of Top Ten Best-Selling Oncology Drugs in China and the U.S. in 2019
PharmaSources/Caicai
December 24, 2020
Information on the top ten best-selling oncology drugs in China and the U.S. in 2019 has recently been released by a related consulting agency of the industry.
-
NICE approves cost-comparison fast-track appraisal pilot
europeanpharmaceuticalreview
August 03, 2021
A new approach to the cost-comparison fast-track appraisal process is being piloted this summer for the review of low-risk appraisals.
-
A Comparison of the Biosimilar Accessibility in China, the EU, and the U.S.: China’s Biosimilars Commercialized at an Impressive Speed
PharmaSources/1°C
February 04, 2020
Biosimilars significantly reduce patients’ burden and boost the life science innovation to benefit more people!
-
UK performs badly in international comparison of health of young people
pharmaceutical-technology
February 21, 2019
An international comparative study found that despite young people in the UK making better choices about their health, particularly in terms of alcohol consumption and smoking....
-
Included in the Medical Insurance of China, A Comparison of Prices of Anticancer Drugs in and outside China
1℃
October 24, 2018
Maximum Price Reduction by 74%!
-
A Comparison of Update Cycle and Characteristics of Pharmacopeia of each country (2)
muzhang
March 19, 2018
Update Cycle and Characteristics of Pharmacopeia of USP, BP and EP
-
A Comparison of Update Cycle and Characteristics of Pharmacopeia of Each Country (1)
muzhang
March 19, 2018
Pharmacopeia is the code of a country to record the pharmaceutical product standards and specifications...
-
Lilly posts impressive psoriasis results in comparison study
pharmafile
March 07, 2017
Eli Lilly has revealed strong results in a study comparing its psoriasis treatment, Taltz (ixekizumab), to Johnson & Johnson’s Stelara. The study was...
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
